Arm Holdings plc vs Inovio Pharmaceuticals Inc — how do they compare? Arm Holdings plc trades at $272.5 (market cap $287.22B), while Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M). The key difference: Arm Holdings plc is far larger — about 3656.5× Inovio Pharmaceuticals Inc's market cap, and Arm Holdings plc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ARM | INO | |
|---|---|---|
Market Cap | $287.22B | $78.55M |
Sector | Technology | Health |
52-Week High | $439.46 | $2.87 |
52-Week Low | $104.55 | $0.66 |
Enterprise Value | $283.79B | $49.56M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →